BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the recipient of unusually large options trading activity on Wednesday. Traders acquired 1,200 call options on the stock. This represents an increase of approximately 943% compared to the typical volume of 115 call options.
BCRX has been the subject of several recent analyst reports. Royal Bank of Canada initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, September 14th. They set a “sector perform” rating and a $6.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, November 8th. Finally, Barclays initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, December 20th. They set an “equal weight” rating and a $6.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $8.63.
In other news, CMO William P. Sheridan sold 64,310 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $4.72, for a total value of $303,543.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.80% of the stock is owned by company insiders.
Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in BioCryst Pharmaceuticals by 19.9% during the second quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock valued at $33,404,000 after purchasing an additional 996,052 shares during the last quarter. OxFORD Asset Management LLP bought a new stake in BioCryst Pharmaceuticals during the second quarter valued at approximately $660,000. RA Capital Management LLC lifted its position in BioCryst Pharmaceuticals by 47.9% during the second quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock valued at $28,702,000 after purchasing an additional 1,672,447 shares during the last quarter. VHCP Management II LLC lifted its position in BioCryst Pharmaceuticals by 27.9% during the third quarter. VHCP Management II LLC now owns 3,165,457 shares of the biotechnology company’s stock valued at $16,587,000 after purchasing an additional 690,290 shares during the last quarter. Finally, Swiss National Bank lifted its position in BioCryst Pharmaceuticals by 49.9% during the third quarter. Swiss National Bank now owns 171,300 shares of the biotechnology company’s stock valued at $898,000 after purchasing an additional 57,000 shares during the last quarter. Institutional investors and hedge funds own 84.69% of the company’s stock.
Shares of BioCryst Pharmaceuticals (BCRX) opened at $5.61 on Monday. BioCryst Pharmaceuticals has a 1 year low of $3.95 and a 1 year high of $9.25. The stock has a market cap of $552.05, a P/E ratio of -8.77 and a beta of 3.05. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.53 and a current ratio of 2.53.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.18). BioCryst Pharmaceuticals had a negative net margin of 167.58% and a negative return on equity of 123.16%. The business had revenue of $8.76 million during the quarter, compared to analyst estimates of $5.05 million. During the same period in the previous year, the business posted ($0.16) earnings per share. BioCryst Pharmaceuticals’s revenue for the quarter was up 12.9% on a year-over-year basis. equities research analysts anticipate that BioCryst Pharmaceuticals will post -0.71 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This article was published by Equities Focus and is owned by of Equities Focus. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.equitiesfocus.com/2018/01/08/traders-buy-high-volume-of-call-options-on-biocryst-pharmaceuticals-bcrx.html.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.